HC Wainwright & Co. Maintains Buy on Leap Therapeutics, Raises Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a 'Buy' rating on Leap Therapeutics and raises the price target from $2.5 to $7.
August 15, 2023 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Leap Therapeutics' price target has been raised from $2.5 to $7 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The increase in price target by HC Wainwright & Co. indicates a positive outlook for Leap Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100